Oric Pharmaceuticals, Inc.
About Oric Pharmaceuticals, Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$129.5M
- Total assets
- $408.9M
- Market cap
- $776.4M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $143.0M
- Operating income
- -$143.0M
- Income tax
- $0
- Net income
- -$129.5M
- EPS (basic)
- $-1.47
- EPS (diluted)
- $-1.47
Balance sheet
- Total assets
- $408.9M
- Current assets
- $288.5M
- Total liabilities
- $24.5M
- Current liabilities
- $20.4M
- Shareholders’ equity
- $384.4M
Cash flow
- Operating cash flow
- -$111.0M
- Investing cash flow
- -$148.0M
- Financing cash flow
- $245.3M
- Net cash flow
- -$13.7M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $776.4M
- EPS (diluted)
- $-1.47
- Shares outstanding
- 103.1M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Apr 24, 2020
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $129.5M.
- Trading 48% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Oric Pharmaceuticals, Inc..
Write a review
News about Oric Pharmaceuticals, Inc.
News & sentiment via Polygon.io
